Biotech entity
CMND-100 is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 56-day window averages about 0.3 stories each week. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category.
Last mentioned: Sep 4, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
CMND-100 is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 56-day window averages about 0.3 stories each week. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. The average consequence score is 6, matching the 6 beat baseline for this window. Each story carries 4 original sources on average, compared with 3.6 for the broader beat in this window. U.S. Department of Health and Human Services (HHS) appears in 2 tracked Biotech stories published from July 11, 2026 through September 4, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 260 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering U.S. Department of Health and Human Services (HHS). Shared-story counts are live from our verified record — not editorial picks.
Lower drug prices are being pursued through voluntary deals rather than enforceable regulation, a September 2026 report finds. For biopharma, the result is reputational pressure without legal clarity, and 'victories' that have yet to materialize.
Source: dailylocal.com · troyrecord.com
Clearmind Medicine submitted a response to an HHS RFI highlighting its clinical-stage candidate CMND-100, an MEAI-based neuroplastogen for Alcohol Use Disorder. The drug engages 5-HT1A pathways without hallucinogenic effects, offering a novel mechanism for addiction treatment.
Source: Nynewscast · Financialcontent
U.S. Department of Health and Human Services (HHS) is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
